US and European Targeted Anti-Cancer Agent Approvals Announced

The US Food and Drug Administration has approved several new targeted anti-cancer agents, while the European Medicines Agency has extended indications for several therapies

medwireNews: The US Food and Drug Administration (FDA) has approved the use of dinutuximab for the treatment of children with high-risk neuroblastoma who have previously achieved at least a partial response to multimodal therapy.

The monoclonal antibody against the GD2 ganglioside is the first ever therapy specifically targeting the condition and will be given alongside interleukin-2, granulocyte–macrophage colony-stimulating factor (GM-CSF) and isotretinoin.

“[Dinutuximab] fulfills a critical need by providing a treatment option that prolongs survival in children with high-risk neuroblastoma”, commented Richard Pazdur, from the FDA Center for Drug Evaluation and Research in Silver Spring, Maryland, in a press release.

The priority review decision follows phase III trial results from the ANBL0032 study comparing the isotretinoin, interleukin-2 and GM-CSF regimen with or without dinutuximab in 226 children with newly diagnosed high-risk neuroblastoma.

Patients given the targeted therapy had significantly higher 3-year rates for event-free survival than those given the standard regimen, at 63% versus 46%, and overall survival, at 73% versus 58%.

The FDA has also recently given approval for several other targeted anti-cancer treatments.

This includes approval for the PDL-1 inhibitor nivolumab for the treatment of metastatic squamous non-small-cell lung cancer (NSCLC) in patients with disease progression after or during platinum-based chemotherapy.

Panobinostat was granted approval as a third-line treatment for multiple myeloma patients, to be given alongside bortezomib and dexamethasone, while lenvatinib was approved for patients with iodine-refractory differentiated thyroid cancer after local recurrence or metastatic progression.

Meanwhile, the European Medicines Agency’s Committee for Medicinal Products for Human Use published a positive opinion recommending conditional marketing authorisation for the use of ceritinib in patients with anaplastic lymphoma kinase-positive, advanced NSCLC who have previously received crizotinib.

Positive opinion for authorisation was also given for new indications for bevacizumab – for the treatment of persistent, recurrent or metastatic cervix carcinoma in combination with paclitaxel, and cisplatin or topotecan – and for panitumumab in patients with Wild-type Ras metastatic colorectal cancer.

Pnitumumab should be given as a first-line treatment in combination with FOLFOX or FOLFIRI chemotherapy regimens.

The anti-Epidermal growth factor receptor monoclonal antibody may also be given as a second-line treatment alongside FOLFIRI in patients who have previously been treated with fluoropyrimidine-based chemotherapy or as a single treatment after treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based regimens.

References

FDA website, visited last time 16 March 2015

EMA website, visited last time 16 March 2015

medwireNews (www.medwireNews.com) is an independent clinical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2015